Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Description

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Conditions

Lung Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Condition
Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Palo Alto

Stanford University, Palo Alto, California, United States, 94305

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
  • * ECOG performance status of 0-2
  • * Age \> 18 years old
  • * Ability to understand and the willingness to personally sign the written IRB approved informed consent document
  • * Estimated life expectancy of 12 weeks or longer
  • * Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
  • * Age \< 18 years old
  • * Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
  • * Diagnosis of interstitial pulmonary fibrosis
  • * Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stanford University,

Lucas K Vitzthum, MD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

2026-12